专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明申请

US20040077666A1 Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents 有权
标题翻译：氮取代的联芳基嘌呤衍生物作为有效的抗增殖剂
公开(公告)号：US20040077666A1
公开(公告)日：2004-04-22
申请号：US10680832
申请日：2003-10-07
发明人： Michael Peter Trova
IPC分类号： A61K031/52 , C07D473/14
CPC分类号： C07D473/34 , C07D473/16 , C07D473/18 , C07D473/24
摘要： The compounds of the present invention are 2,6,9-trisubstituted purine derivatives which are inhibitors of cyclin/cdk complexes. The compounds of the current invention also are potent inhibitors of human cellular proliferation. As such, the compounds of the present invention constitute pharmaceutical compositions with a pharmaceutically acceptable carrier. Such compounds are useful in treating a disorder mediated by elevated levels of cell proliferation in a mammal compared to a healthy mammal by administering to such mammal an effective amount of the compound. Examples of the compounds of the present invention are represented by the following chemical structures: 1 with X, Y, D, Q, V, A, R1, R2, R3, R4, and n1 defined herein.
摘要翻译：本发明的化合物是2,6,9-三取代的嘌呤衍生物，其是细胞周期蛋白/ cdk复合物的抑制剂。本发明的化合物也是人细胞增殖的有效抑制剂。因此，本发明的化合物构成具有药学上可接受的载体的药物组合物。通过向这些哺乳动物施用有效量的该化合物，这些化合物可用于治疗与哺乳动物相比，通过升高的哺乳动物细胞增殖水平介导的病症。本发明化合物的实例由以下化学结构表示：本文定义的X，Y，D，Q，V，A，R 1，R 2，R 3，R 4和n 1。

42. 发明授权

US4565817A Theophyllinyl-alkyl-oxadiazoles, process for the preparation thereof and pharmaceutical compositions containing same 失效
标题翻译：木脂基 - 烷基 - 恶二唑，其制备方法和含有它们的药物组合物
公开(公告)号：US4565817A
公开(公告)日：1986-01-21
申请号：US474227
申请日：1983-03-11
申请人： Dezso Korbonits , Maria Szomor nee Wundele , Gergely Heja , Ida Szvoboda nee Kanzel , Pal Kiss , Csaba Gonczi , Endre Palosi , Gabor Kovacs , Judit Kun , Emil Minker , Sandor Virag , Gyula Sebestyen , Tamas Szuts
发明人： Dezso Korbonits , Maria Szomor nee Wundele , Gergely Heja , Ida Szvoboda nee Kanzel , Pal Kiss , Csaba Gonczi , Endre Palosi , Gabor Kovacs , Judit Kun , Emil Minker , Sandor Virag , Gyula Sebestyen , Tamas Szuts
IPC分类号： C07D413/06 , A61K31/52 , A61K31/522 , A61P11/00 , A61P11/08 , A61P11/14 , A61P29/00 , A61P31/14 , C07D20060101 , C07D271/06 , C07D401/14 , C07D473/08 , C07D473/14 , C07D473/10
CPC分类号： C07D473/08
摘要： Antitussive compounds of the formula I ##STR1## or physiologically acceptable acid addition salts thereof are disclosed, where A stands for straight or branched chain C.sub.1-5 alkylene or ##STR2## R.sub.1 stands for straight or branched chain C.sub.1-10 alkyl, halogenoalkyl, hydroxyalkyl, C.sub.5-6 cycloalkyl, vinyl, 2-ethoxyethyl, carbonylalkyl or aminoalkyl of the formula ##STR3## wherein R stands for hydrogen or methyl, n is 0 to 3,R.sub.2 stands for hydrogen or straight or branched chain alkyl,R.sub.3 stands for hydrogen or straight or branched chain alkyl or,R.sub.2 and R.sub.3 together with the nitrogen atom may form a 5-6 membered ring, which ring can optionally contain an oxygen or a second nitrogen atom, the latter, optionally substituted by methyl or,R.sub.1 can stand for a phenyl group of the formulaR.sub.4 R.sub.5 C.sub.6 H.sub.3 whereinR.sub.4 and R.sub.5 represent independently hydrogen, chlorine, hydroxy, methoxy, ethoxy, methyl or amino or,R.sub.1 may further stand for hydroxy, in this case the compound of the formula I may exist according to the conditions in the form of tautomers of the formula Ia ##STR4## and R.sub.1 may further stand for benzyl, 2,2-diphenylethyl or theophyllin-7-yl-methyl.
摘要翻译：公开了式I的镇咳药（I）或其生理上可接受的酸加成盐，其中A代表直链或支链C 1-5亚烷基，或者R 1代表直链或支链C 1-10烷基，卤代烷基，羟基烷基，C 5-6环烷基，乙烯基，2-乙氧基乙基，羰基烷基或下式的氨基烷基其中R代表氢或甲基，n为0-3，R2代表氢或直链或支链烷基，R3 代表氢或直链或支链烷基，或者R2和R3与氮原子一起可以形成5-6元环，该环可以任选地含有氧或第二氮原子，后者任选地被甲基或 R1可以代表式为R4R5C6H3的苯基，其中R4和R5独立地表示氢，氯，羟基，甲氧基，乙氧基，甲基或氨基，或者R1可以进一步代表羟基，在这种情况下可以存在式I化合物根据式Ia（Ia）或（Ib）和R1的互变异构体形式的条件可以进一步代表苄基，2,2-二苯基乙基或甲茶素-7-基 - 甲基。

43. 发明申请

US20070093510A1 Phosphodiesterase 4 inhibitors 失效
标题翻译：磷酸二酯酶4抑制剂
公开(公告)号：US20070093510A1
公开(公告)日：2007-04-26
申请号：US10636979
申请日：2003-08-08
申请人： Ashok Tehim , Allen Hopper , Ruiping Liu , Hans-Jurgen Hess , Yajing Rong
发明人： Ashok Tehim , Allen Hopper , Ruiping Liu , Hans-Jurgen Hess , Yajing Rong
IPC分类号： A61K31/52 , C07D473/14
CPC分类号： C07D473/34 , C07D473/14
摘要： PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein.
摘要翻译：通过式I的新化合物实现PDE4抑制：其中R 1和R 2如本文所定义。

44. 发明申请

US20070060598A1 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith 有权
标题翻译：卤代芳基取代的氨基嘌呤，其组合物及其处理方法
公开(公告)号：US20070060598A1
公开(公告)日：2007-03-15
申请号：US11411413
申请日：2006-04-26
申请人： Ronald Albers , Leticia Ayala , Steven Clareen , Maria Delgado Mederos , Robert Hilgraf , Sayee Hegde , Kevin Hughes , Adam Kois , Veronique Plantevin-Krenitsky , Meg McCarrick , Lisa Nadolny , Moorthy Palanki , Kiran Sahasrabudhe , John Sapienza , Yoshitaka Satoh , Marianne Sloss , Elise Sudbeck , Jonathan Wright
发明人： Ronald Albers , Leticia Ayala , Steven Clareen , Maria Delgado Mederos , Robert Hilgraf , Sayee Hegde , Kevin Hughes , Adam Kois , Veronique Plantevin-Krenitsky , Meg McCarrick , Lisa Nadolny , Moorthy Palanki , Kiran Sahasrabudhe , John Sapienza , Yoshitaka Satoh , Marianne Sloss , Elise Sudbeck , Jonathan Wright
IPC分类号： A61K31/52 , C07D473/14
CPC分类号： A61K31/52 , C07D473/32
摘要： Provided herein are Aminopurine Compounds having the following structure: wherein R1, R2 and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.
摘要翻译：本文提供具有以下结构的氨基嘌呤化合物：其中R 1，R 2和R 3如本文所定义，包含有效量的组合物的氨基嘌呤化合物和治疗或预防癌症，心血管疾病，肾脏疾病，自身免疫病症，炎性病症，黄斑变性，缺血再灌注损伤，疼痛和相关综合征，疾病相关性消耗，石棉相关的方法条件，肺动脉高压或通过抑制JNK途径可治疗或可预防的病症，包括向有需要的患者施用有效量的氨基嘌呤化合物。

45. 发明申请

US20070037975A1 Substituted-1,3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties 审中-公开
标题翻译：取代-1,3-氧硫杂环戊烷和具有抗病毒性质的取代-1,3-二氧戊环
公开(公告)号：US20070037975A1
公开(公告)日：2007-02-15
申请号：US11580866
申请日：2006-10-16
申请人： Bernard Belleau , Dilip Dixit , Nghe Nguyen-Ba , Pierette Belleau
发明人： Bernard Belleau , Dilip Dixit , Nghe Nguyen-Ba , Pierette Belleau
IPC分类号： C07D473/14 , C07D473/02 , C07D411/02 , C07D487/02
CPC分类号： C07D411/14 , C07D327/04 , C07D405/04 , C07D411/04 , C07D473/00 , C07D473/40 , H02M1/08
摘要： Disclosed are compounds of the formula wherein R1 is hydrogen or an acyl group having 1 to 16 carbon atoms; R2 is a purine or pyrimidine base or an analogue or derivative thereof; Z is O, S, S═O or SO2; and pharmaceutically acceptable derivatives thereof. Also described are processes for and intermediates of use in their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds in the antiviral treatment of mammals.
摘要翻译：公开了下式的化合物其中R 1是氢或具有1至16个碳原子的酰基; R 2是嘌呤或嘧啶碱基或其类似物或衍生物; Z是O，S，S-O或SO 2; 及其药学上可接受的衍生物。还描述了其制备中使用的方法和中间体，含有这些化合物的药物组合物，以及这些化合物在哺乳动物的抗病毒治疗中的用途。

46. 发明申请

US20070010535A1 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological atates 失效
标题翻译：作为治疗剂的镁结合缺陷的拮抗剂和治疗异常生理学的方法
公开(公告)号：US20070010535A1
公开(公告)日：2007-01-11
申请号：US11512024
申请日：2006-08-29
申请人： Ibert Clifton
发明人： Ibert Clifton
IPC分类号： A61K31/52 , C07D473/14
CPC分类号： C07C237/20 , A61K31/16 , A61K31/165 , C07C237/12 , C07C237/22 , G01N2800/042 , G01N2800/321
摘要： This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans, trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstituted propanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds.
摘要翻译：本发明提供一类治疗化合物和治疗哺乳动物的方法，所述哺乳动物具有生理紊乱，例如经常发生的原发性高血压，其与镁与其细胞的质膜结合减少有关。这些方法包括对需要这种治疗的哺乳动物施用选自一系列二取代的反式，反式1,3-丁二烯，1,3-二取代的全氢丁二烯，1,2-二取代的反式亚乙基和1,2-二取代的乙烷的化合物和二取代的丙烷，它们各自共同体现了这些化合物的生物活性所必需的独特的结构特征。本发明还提供了使用这些新化合物的药物制剂。

47. 发明申请

US20060142570A1 Benzazole analogues and uses thereof 失效
公开(公告)号：US20060142570A1
公开(公告)日：2006-06-29
申请号：US11317909
申请日：2005-12-22
申请人： Thomas Herz , Rolf Krauss , Michael Kubbutat , Martin Lang , Christoph Schaechtele , Stefan Tasler , Frank Totzke
发明人： Thomas Herz , Rolf Krauss , Michael Kubbutat , Martin Lang , Christoph Schaechtele , Stefan Tasler , Frank Totzke
IPC分类号： C07D473/14 , C07D487/02 , C07D417/02
CPC分类号： C07D417/12 , C07D413/12 , C07D417/14 , C07D473/34
摘要： The present invention relates to compounds of the general formulas (I), (Ia) and (II) and salts and physiologically functional derivatives thereof, wherein the substituents —Y are attached to the 5- or 6-position of the benzazole.

48. 发明申请

US20060106256A1 Substituted hydroxyethylamines 失效
标题翻译：取代羟乙基胺
公开(公告)号：US20060106256A1
公开(公告)日：2006-05-18
申请号：US10505947
申请日：2003-02-27
申请人： Varghese John , Barbara Jagodzinska , Michel Maillard , James Beck , Ruth TenBrink , Daniel Getman
发明人： Varghese John , Barbara Jagodzinska , Michel Maillard , James Beck , Ruth TenBrink , Daniel Getman
IPC分类号： C07D475/14 , C07D473/14 , C07D265/36 , C07D279/18 , C07D471/02 , C07D215/38 , C07D277/82
CPC分类号： C07D307/20 , A61K47/556 , C07C217/58 , C07C233/78 , C07C247/10 , C07C247/12 , C07C255/57 , C07C271/16 , C07C271/20 , C07C2601/14 , C07C2602/10 , C07C2603/18 , C07D209/08 , C07D213/82 , C07D231/26 , C07D249/18 , C07D295/205 , C07D295/26 , C07D303/36 , C07D317/68 , C07D417/12
摘要： This invention relates to prodrugs of a class of amine compounds which are useful in the treatment of Alzheimer's disease and similar diseases.
摘要翻译：本发明涉及可用于治疗阿尔茨海默病和类似疾病的一类胺化合物的前药。

49. 发明申请

US20060052403A1 Novel adenine compound and use thereof 失效
标题翻译：新型腺嘌呤化合物及其用途
公开(公告)号：US20060052403A1
公开(公告)日：2006-03-09
申请号：US10528343
申请日：2003-09-26
申请人： Yoshiaki Isobe , Haruo Takaku , Haruhisa Ogita , Masanori Tobe , Ayumu Kurimoto , Tetsuhiro Ogino , Hitoshi Fujita
发明人： Yoshiaki Isobe , Haruo Takaku , Haruhisa Ogita , Masanori Tobe , Ayumu Kurimoto , Tetsuhiro Ogino , Hitoshi Fujita
IPC分类号： A61K31/52 , C07D473/12 , C07D473/14
CPC分类号： A61K31/5377 , A61K31/522 , A61K31/55
摘要： A drug for topically administration which is effective as an antiallergic agent. The drug for topically administration contains as an active ingredient an adenine compound represented by the general formula (1): [wherein ring A represents a 6 to 10 membered, mono or bicyclic, aromatic hydrocarbon or a 5 to 10 membered, mono or bicyclic, aromatic heterocycle containing one to three heteroatoms selected among 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom; n is an integer of 0 to 2; m is an integer of 0 to 2; R represents halogeno, (un)substituted alkyl, etc.; X1 represents oxygen, sulfur, NR1 (R1 represents hydrogen or alkyl), or a single bond; Y1 represents a single bond, alkylene, etc.; Y2 represents a single bond, alkylene, etc.; Z represents alkylene; and at least one of Q1 and Q2 represents —COOR10 (wherein R10 represents (un)substituted alkyl, etc.), etc.] or a pharmaceutically acceptable salt of the compound.
摘要翻译：用作局部给药的药物，其作为抗过敏剂有效。用于局部给药的药物含有由通式（1）表示的腺嘌呤化合物作为活性成分：

50. 发明申请

US20060008835A1 PNA monomer and precursor 有权
公开(公告)号：US20060008835A1
公开(公告)日：2006-01-12
申请号：US11182672
申请日：2005-07-15
申请人： Sung Kim , Hyunil Lee , Jong Lim , Hoon Choi , Jae Jeon , Sang Ahn , Sung Lee , Won Yoon
发明人： Sung Kim , Hyunil Lee , Jong Lim , Hoon Choi , Jae Jeon , Sang Ahn , Sung Lee , Won Yoon
IPC分类号： C12Q1/68 , C07D473/14
CPC分类号： C07D417/04 , C07B2200/11 , C07D277/80 , C07D417/12 , C07D417/14 , Y02P20/55
摘要： This application relates to monomers of the general formula (I) for the preparation of PNA (peptide nucleic acid) oligomers and provides method for the synthesis of both predefined sequence PNA oligomers and random sequence PNA oligomers: wherein E is nitrogen or C—R′; J is sulfur or oxygen; R′, R1, R2, R3, R4 is independently H, halogen, alkyl, nitro, nitrile, alkoxy, halogenated alkyl, halogenated alkoxy, phenyl or halogenated phenyl, R5 is H or protected or unprotected side chain of natural or unnatural α-amino acid; and B is a natural or unnatural nucleobase, wherein when said nucleobase has an exocyclic amino function, said function is protected by protecting group which is labile to acids but stable to weak to medium bases in the presence of thiol.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式